Seres Therapeutics, Inc.
corporate_fare Company Profile
Seres Therapeutics, Inc. (NASDAQ:MCRB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 19 items for MCRB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 8/10. Across its 19 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for MCRB spans 10-Q, 8-K, DEF 14A, 10-K.
Recent high-impact activity:
- Seres 10-Q: $16.3M Q3 Loss, $17.5M Cash, Going Concern Reaffirmed
- Seres Posts $16.3M Q3 Loss, Pivots SER-155 Toward irEC Prevention With Cash Through Q1 2027
- Seres Posts $16.3M Q3 Loss, Cash Lasts Only Through Q1 2027
- Seres Therapeutics CFO Marella Thorell to Resign Effective November 15, 2026
- Seres Therapeutics Swings to a $4.6M Q2 Profit on Nestlé Payment, but Going Concern Warning Lingers
Financial Snapshot
Short Interest & Short Volume
4.31 days to coverFINRA reported short interest of 342,237 shares in MCRB as of the October 30, 2026 settlement, a 9.6% increase from the prior period — about 4.3 days to cover at its recent average daily volume. On November 20, 2026, 31.2% of MCRB volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for MCRB, detected from its recent SEC filings · based on capital-structure filings through 2026-08-04.
Lease Termination Payment in Stock · No Proceeds to Company
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →